18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage:
http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=1332338&highlight=
http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=1332338&highlight=